Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
24.80
+0.37 (1.51%)
At close: Apr 28, 2026, 4:00 PM EDT
24.80
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Agios Pharmaceuticals Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Agios Pharmaceuticals stock have an average target of 38.88, with a low estimate of 28 and a high estimate of 50. The average target predicts an increase of 56.77% from the current stock price of 24.80.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Agios Pharmaceuticals stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 2 | 1 | 1 | 1 | 1 | 1 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Strong Buy Maintains $44 → $41 | Strong Buy | Maintains | $44 → $41 | +65.32% | Apr 21, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $65 → $50 | Strong Buy | Maintains | $65 → $50 | +101.61% | Apr 20, 2026 |
| JP Morgan | JP Morgan | Hold Maintains $31 → $36 | Hold | Maintains | $31 → $36 | +45.16% | Apr 6, 2026 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $28 → $32 | Hold | Maintains | $28 → $32 | +29.03% | Apr 1, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $38 → $46 | Strong Buy | Maintains | $38 → $46 | +85.48% | Mar 5, 2026 |
Financial Forecast
Revenue This Year
95.49M
from 54.03M
Increased by 76.75%
Revenue Next Year
258.53M
from 95.49M
Increased by 170.73%
EPS This Year
-6.75
from -7.12
EPS Next Year
-5.27
from -6.75
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 122.3M | 366.9M | ||||||
| Avg | 95.5M | 258.5M | ||||||
| Low | 65.7M | 154.4M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 126.4% | 284.2% | ||||||
| Avg | 76.7% | 170.7% | ||||||
| Low | 21.5% | 61.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -6.05 | -4.05 | ||||||
| Avg | -6.75 | -5.27 | ||||||
| Low | -7.00 | -6.12 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.